Home » Medical Devices » Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Others) By End User (Reference Laboratories, Hospitals & Physician Laboratories, Others)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global breast cancer liquid biopsy market is segmented by circulating biomarker, end user, and region. Circulating tumor cells (CTCs) dominate the biomarker segment, while hospitals & physician laboratories are the leading end users. North America and Europe are the largest markets, driven by advanced healthcare infrastructure and stringent regulatory standards.

The breast cancer liquid biopsy market is driven by factors such as the increasing incidence of breast cancer worldwide, the need for early and accurate detection methods, advancements in liquid biopsy technologies, and the growing focus on precision medicine in cancer treatment. However, the market faces challenges such as the high cost of liquid biopsy tests, regulatory complexities surrounding liquid biopsy approval and reimbursement, and the need for further validation and standardization of liquid biopsy techniques.

Nonetheless, the global breast cancer liquid biopsy market presents opportunities for growth due to the rising demand for non-invasive diagnostic tools, the development of targeted therapies based on liquid biopsy results, the integration of artificial intelligence & machine learning in liquid biopsy analysis, and the expansion of the market in emerging economies with improving healthcare infrastructure.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global breast cancer liquid biopsy market has witnessed steady growth in recent years and is expected to grow at a CAGR of 22.7% between 2023 and 2030. The market was valued at USD 0.3 billion in 2022 and is expected to reach USD 1.25 billion in 2030.

What Are The Main Drivers Of The Global Breast Cancer Liquid Biopsy Market?

The major drivers of the global breast cancer liquid biopsy market growth are the increasing incidence of breast cancer, growing demand for non-invasive and early detection methods, advancements in liquid biopsy technologies, and the potential to provide real-time monitoring of treatment response and disease progression. Besides, the rising emphasis on personalized medicine and the need for improved patient outcomes drive the adoption of liquid biopsy techniques in breast cancer management, further fueling market expansion.

What Are The Major Challenges Faced By The Global Breast Cancer Liquid Biopsy Market?

The major challenges faced by the global breast cancer liquid biopsy market are the complexity of biomarker analysis and interpretation, variability in assay performance and sensitivity, limited standardization and regulatory guidelines, and the need for robust validation studies to establish clinical utility and reliability. Also, the high cost of liquid biopsy tests and the reimbursement landscape poses challenges for widespread adoption, along with the need for larger-scale clinical studies to demonstrate liquid biopsy’s clinical utility and validity in breast cancer management.

What Are The Growth Opportunities In The Global Breast Cancer Liquid Biopsy Market?

The growth opportunities in the global breast cancer liquid biopsy market include the development of more sensitive and specific liquid biopsy technologies, integration of multi-omics analysis for comprehensive profiling, exploration of novel biomarkers for early detection and treatment monitoring, expanding applications beyond diagnosis, and increasing awareness and education among healthcare professionals and patients.

Executive Summary

Overview of the Global Breast Cancer Liquid Biopsy Market

The breast cancer liquid biopsy market is a rapidly evolving field in diagnosing and monitoring breast cancer. Liquid biopsy is the non-invasive detection and analysis of tumor-specific biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles in blood or other body fluids. This approach offers a less invasive alternative to traditional tissue biopsies and provides valuable insights into tumor characteristics, treatment response, and disease progression. The market is driven by factors such as the rising incidence of breast cancer, emerging demands for early detection methods, advancements in liquid biopsy technologies, and the potential for real-time monitoring of treatment efficacy.

Market Definition

The breast cancer liquid biopsy market encompasses developing and commercializing diagnostic tools and technologies for detecting, analyzing, and monitoring breast cancer using liquid biopsy techniques. This includes collecting and analyzing circulating tumor biomarkers, such as ctDNA and CTCs, from blood samples or other body fluids. The market includes various liquid biopsy assays, platforms, and kits designed to detect and quantify these biomarkers and associated software and data analysis tools. The goal is to provide clinicians with valuable information for accurate diagnosis, treatment decision-making, and monitoring of breast cancer patients.

Market Insights

The global demand for breast cancer liquid biopsy was valued at USD 0.3 Billion in 2022 and is expected to reach USD 1.25 Billion in 2030, growing at a CAGR of 22.7% between 2023 and 2030.
Circulating tumor cells (CTCs) are the leading segment by circulating biomarker and held over 35% share in terms of value in 2022, while the cell-free DNA (cfDNA) segment is likely to exhibit the fastest CAGR in the forecast period.
The hospitals & physician laboratories end-user segment dominates the global demand for breast cancer liquid biopsy, holding a significant share of over 40% in 2022, and is expected to grow at a rapid CAGR.
North America dominated the industry in 2022, accounting for more than 44% of global market revenue owing to the well-established healthcare infrastructure, strong R&D activities, and increasing awareness among healthcare professionals and patients.
The Asia-Pacific region is projected to witness substantial growth in the coming years, fueled by the growing prevalence of breast cancer, rising healthcare expenditure, and emerging adoption of advanced diagnostic technologies.
Liquid biopsy offers several advantages over traditional tissue biopsies, such as its non-invasive nature, ability to monitor treatment response, and potential for early detection of tumor recurrence.

Segmentation by Circulating Biomarker

Circulating tumor cells (CTCs) dominate the segment, contributing to over 35% of the market share in terms of value in 2022.
The cell-free DNA (cfDNA) segment is expected to exhibit the fastest CAGR in the projected period, driven by technological advancements and its potential for non-invasive cancer detection.

Segmentation by End User

The reference laboratories segment is projected to post the highest CAGR over the estimated period, owing to the growing demand for accurate and specialized diagnostic services.
The hospitals & physician laboratories segment led the global market in 2022, holding over 40% share in terms of value. These facilities play a critical role in breast cancer diagnosis and management.

Segmentation by Region

North America dominated the global breast cancer liquid biopsy market in 2022, accounting for over 44% of revenue share.
Europe is another prominent global breast cancer liquid biopsy market, contributing substantially to the overall market share.
The Asia-Pacific region is experiencing rapid growth, with a high CAGR in the breast cancer liquid biopsy industry.
The rest of the World, including regions like the Middle East, Latin America, and Africa, is witnessing the rapid adoption of breast cancer liquid biopsy solutions.

The global breast cancer liquid biopsy market is driven by factors such as the emerging incidence of breast cancer, increasing demand for non-invasive diagnostic methods, and advancements in liquid biopsy technologies. However, the market faces restraints in the form of high costs associated with liquid biopsy tests, regulatory challenges, and the need for skilled healthcare professionals.

The United States is a major country in the global breast cancer liquid biopsy market. The country has a well-established healthcare infrastructure, advanced research facilities, and a higher incidence of breast cancer. The United States is at the forefront of technological advancements and innovation in the healthcare sector. The presence of key market players, research institutions, and regulatory bodies further contributes to the growth of the country’s breast cancer liquid biopsy market. The U.S. also strongly focuses on personalized medicine and precision oncology, driving the adoption of liquid biopsy technologies for better patient outcomes.

China represents a significant opportunity in the breast cancer liquid biopsy industry. The country has a large population, a rising incidence of breast cancer, and a growing healthcare infrastructure. The Chinese government has invested in developing precision medicine and encouraging R&D in liquid biopsy. With an increasing emphasis on early detection and personalized treatment, there is a growing demand for non-invasive diagnostic methods like liquid biopsy in China. A robust biotechnology industry, academic collaborations, and a large patient pool make China a key breast cancer liquid biopsy technology market.

Increasing Demand for Non-Invasive Diagnostic Methods

The growing demand for non-invasive diagnostic methods drives the adoption of breast cancer liquid biopsy. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, reducing patient discomfort and potential complications. The need for early detection and personalized treatment strategies further fuels the demand for non-invasive techniques.

Advancements in Liquid Biopsy Technologies

Technological advancements in liquid biopsy techniques and platforms have significantly enhanced their sensitivity, specificity, and reliability. Improvements in the detection and analysis of circulating tumor biomarkers, such as ctDNA and CTCs, have enabled more accurate diagnosis, treatment monitoring, and disease prognosis. These advancements drive the market by providing healthcare professionals with valuable insights for clinical decision-making.

Regulatory Challenges and Standardization

The breast cancer liquid biopsy market faces regulatory challenges and the need for standardization. Ensuring the accuracy, reliability, and consistency of liquid biopsy tests and results across different platforms and laboratories is a significant challenge. Regulatory guidelines and approval processes may vary across regions, leading to market entry and commercialization complexities.

High Cost and Limited Reimbursement

The cost of liquid biopsy tests can be relatively high, making it a limiting factor for widespread adoption. Additionally, the reimbursement landscape for liquid biopsy procedures may be limited, impacting the accessibility and affordability of these tests for patients. The high cost and reimbursement challenges can impede market growth, particularly in regions with resource constraints.

Integration of Multi-Omics Analysis

Integrating multi-omics analysis, such as genomics, transcriptomics, and proteomics, in liquid biopsy can comprehensively profile breast cancer tumors. This integration allows for a deeper understanding of tumor heterogeneity, treatment resistance, and disease progression. The ability to analyze multiple biomarkers simultaneously presents an opportunity for market growth and improved patient management.

Competitive Landscape

Key Players

The global breast cancer liquid biopsy market is highly competitive and characterized by the presence of several key players, research institutions, and diagnostic laboratories. Some of the major players in the market and their market share are as follows:

The Menarini Group
NeoGenomics Laboratories
F. Hoffmann-La Roche Ltd
Myriad Genetics Inc
QIAGEN
Biocept Inc
Sysmex Corporation
Fluxion Biosciences Inc
Epic Sciences Inc
Thermo Fisher Scientific Inc

These players strive to develop innovative products, enhance the sensitivity and specificity of assays, and expand their geographical presence. The market is witnessing collaborations and partnerships between industry participants and research institutions to leverage their expertise and accelerate technological advancements. Companies are also investing in research and development activities to develop novel biomarkers and improve the performance of liquid biopsy tests.

For instance, Gene Solutions, a Vietnam-based firm, developed the Screening for the Presence of Tumour by Methylation and Size (SPOT-MAS) – a multimodal liquid biopsy-based assay – on March 1, 2023, to identify the five most common cancer types (liver, breast, colorectal, stomach, and lung cancer). The circulating tumor DNA (ctDNA) assay seeks to detect the presence of ctDNA in blood. This method, colloquially as a ‘liquid biopsy,’ requires only blood samples, not tumor material.

Likewise, REVEAL GENOMICS S.L., a biotechnology start-up in Barcelona that aims to revolutionize precision oncology through biomarker innovation, revealed a new addition to its pipeline in March 2023, consisting of a revolutionary biomarker approach in liquid biopsy for patients with advanced cancer. GENOMICS REVEAL Machine learning-based technology applied to ctDNA predicted treatment response and survival outcomes in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The increasing prevalence of breast cancer in the population and the necessity to deliver detection solutions faster than other tissue biopsy procedures are driving market expansion.
Market segmented by circulating biomarker, end user, and region.
Circulating tumor cells (CTCs) are the dominant biomarker segment, playing a key role in detecting and monitoring breast cancer.
North America and Europe have emerged as major breast cancer liquid biopsy markets, benefiting from advanced healthcare infrastructure and stringent regulatory standards.
The high cost of liquid biopsy tests presents a challenge to market growth, particularly for healthcare facilities with limited budgets.
Technological advancements, including developing more sensitive and specific liquid biopsy assays, contribute to innovations in breast cancer liquid biopsy biomarkers.

Future Outlook

Growing emphasis on personalized medicine and targeted therapies drives the demand for liquid biopsy tests, offering valuable molecular information for treatment decisions and improved patient outcomes.
Expansion of R&D operations focused on identifying novel liquid biopsy biomarkers, such as circulating nucleic acids and exosomes, which hold the potential for enhancing breast cancer detection with improved sensitivity and specificity.
Rising investments in healthcare infrastructure, particularly in emerging economies, are expected to boost the adoption of liquid biopsy technologies, expanding access to advanced diagnostic tools for breast cancer management.

Segmentation

By Circulating Biomarker
- Circulating Tumor Cells (CTCs)
- Cell-free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Others
By End User
- Reference Laboratories
- Hospitals & Physician Laboratories
- Others
By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
2.2. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker
2.3. Global Breast Cancer Liquid Biopsy Market, By End User
2.4. Global Breast Cancer Liquid Biopsy Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Breast Cancer Liquid Biopsy Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Circulating Biomarker
3.5.2. End User
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker
7.1. Global Breast Cancer Liquid Biopsy Market Overview, by Circulating Biomarker
7.1.1. Global Breast Cancer Liquid Biopsy Market Revenue Share, By Circulating Biomarker, 2022 Vs 2030 (in %)
7.2. Circulating Tumor Cells (CTCs)
7.2.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)
7.3. Cell-free DNA (cfDNA)
7.3.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)
7.4. Extracellular Vesicles (EVs)
7.4.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)
7.5. Others
7.5.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)

8. Global Breast Cancer Liquid Biopsy Market, by End User, 2017-2030 (US$ Bn)
8.1. Global Breast Cancer Liquid Biopsy Market Overview, by End User
8.1.1. Global Breast Cancer Liquid Biopsy Market, By End User, 2022 vs 2030 (in%)
8.2. Reference Laboratories
8.2.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)
8.3. Hospitals & Physician Laboratories
8.3.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)
8.4. Others
8.4.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2017-2030 (US$ Bn)

9. Global Breast Cancer Liquid Biopsy Market, By Region
9.1. Global Breast Cancer Liquid Biopsy Market Overview, by Region
9.1.1. Global Breast Cancer Liquid Biopsy Market, By Region, 2022 vs 2030 (in%)
9.2. Circulating Biomarker
9.2.1. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2017-2030 (US$ Bn)
9.3. End User
9.3.1. Global Breast Cancer Liquid Biopsy Market, By End User, 2017-2030 (US$ Bn)

10. North America Breast Cancer Liquid Biopsy Market Analysis
10.1. North America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Breast Cancer Liquid Biopsy Market, by End User, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Breast Cancer Liquid Biopsy Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Breast Cancer Liquid Biopsy Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
10.3.3.3. Canada Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)

11. Europe Breast Cancer Liquid Biopsy Market Analysis
11.1. Europe Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Breast Cancer Liquid Biopsy Market, by End User, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Breast Cancer Liquid Biopsy Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Breast Cancer Liquid Biopsy Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.2.3. Germany Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.3.3. France Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.4.3. UK Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.5.3. Italy Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.6.3. Spain Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)

12. Asia Pacific Breast Cancer Liquid Biopsy Market Analysis
12.1. Asia Pacific Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Breast Cancer Liquid Biopsy Market, by End User, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Breast Cancer Liquid Biopsy Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Breast Cancer Liquid Biopsy Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.2.3. China Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.3.3. Japan Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.4.3. India Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)

13. Latin America Breast Cancer Liquid Biopsy Market Analysis
13.1. Latin America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Breast Cancer Liquid Biopsy Market, by End User, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Breast Cancer Liquid Biopsy Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Breast Cancer Liquid Biopsy Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)

14. Middle East and Africa Breast Cancer Liquid Biopsy Market Analysis
14.1. Middle East and Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Breast Cancer Liquid Biopsy Market, by End User, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Breast Cancer Liquid Biopsy Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Breast Cancer Liquid Biopsy Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Breast Cancer Liquid Biopsy, By Circulating Biomarker, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Breast Cancer Liquid Biopsy, By End User, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. The Menarini Group
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. NeoGenomics Laboratories
15.3. F. Hoffmann-La Roche Ltd
15.4. Myriad Genetics Inc
15.5. QIAGEN
15.6. Biocept Inc
15.7. Sysmex Corporation
15.8. Fluxion Biosciences Inc
15.9. Epic Sciences Inc
15.10. Thermo Fisher Scientific Inc

List of Figures
FIG. 1 Global Breast Cancer Liquid Biopsy Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Breast Cancer Liquid Biopsy Market Segmentation
FIG. 4 Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2022 (US$ Bn)
FIG. 5 Global Breast Cancer Liquid Biopsy Market, by End User, 2022 (US$ Bn)
FIG. 6 Global Breast Cancer Liquid Biopsy Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Circulating Biomarker, 2022
FIG. 8 Attractive Investment Proposition, by End User, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Breast Cancer Liquid Biopsy Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Breast Cancer Liquid Biopsy Market Manufacturers, 2022
FIG. 12 Global Breast Cancer Liquid Biopsy Market Value Contribution, By Circulating Biomarker, 2022 & 2030 (Value %)
FIG. 13 Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), Value, 2017-2030 (US$ Bn)
FIG. 14 Global Breast Cancer Liquid Biopsy Market, by Cell-free DNA (cfDNA), Value, 2017-2030 (US$ Bn)
FIG. 15 Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), Value, 2017-2030 (US$ Bn)
FIG. 16 Global Breast Cancer Liquid Biopsy Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Breast Cancer Liquid Biopsy Market Value Contribution, By End User, 2022 & 2030 (Value %)
FIG. 18 Global Breast Cancer Liquid Biopsy Market, by Reference Laboratories, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Breast Cancer Liquid Biopsy Market, by Hospitals & Physician Laboratories, 2017-2030 (US$ Bn)
FIG. 20 Global Breast Cancer Liquid Biopsy Market, by Others, 2017-2030 (US$ Bn)
FIG. 21 North America Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 22 U.S. Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 23 Canada Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 24 Europe Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 25 Germany Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 26 France Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 27 U.K. Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 28 Italy Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 29 Spain Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 30 Rest of Europe Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 31 Asia Pacific Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 32 China Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 33 Japan Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 34 India Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 35 South Korea Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 36 South-East Asia Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 37 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 38 Latin America Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 39 Brazil Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 40 Mexico Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 41 Rest of Latin America Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 42 Middle East & Africa Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 43 GCC Countries Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 44 South Africa Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)
FIG. 45 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Breast Cancer Liquid Biopsy Market
TABLE 2 Global Breast Cancer Liquid Biopsy Market: Market Drivers Impact Analysis
TABLE 3 Global Breast Cancer Liquid Biopsy Market: Market Restraints Impact Analysis
TABLE 4 Global Breast Cancer Liquid Biopsy Market, by Competitive Benchmarking, 2022
TABLE 5 Global Breast Cancer Liquid Biopsy Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Breast Cancer Liquid Biopsy Market, by Key Strategies Analysis, 2022
TABLE 7 Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Breast Cancer Liquid Biopsy Market, by Cell-free DNA (cfDNA), By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Breast Cancer Liquid Biopsy Market, by Cell-free DNA (cfDNA), By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Breast Cancer Liquid Biopsy Market, by Reference Laboratories, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Breast Cancer Liquid Biopsy Market, by Reference Laboratories, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Breast Cancer Liquid Biopsy Market, by Hospitals & Physician Laboratories, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Breast Cancer Liquid Biopsy Market, by Hospitals & Physician Laboratories, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Breast Cancer Liquid Biopsy Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Breast Cancer Liquid Biopsy Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 20 Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 21 Global Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 22 Global Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 23 Global Breast Cancer Liquid Biopsy Market, by Region, 2017-2022 (US$ Bn)
TABLE 24 Global Breast Cancer Liquid Biopsy Market, by Region, 2023-2030 (US$ Bn)
TABLE 25 North America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 26 North America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 27 North America Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 28 North America Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 29 North America Breast Cancer Liquid Biopsy Market, by Country, 2017-2022 (US$ Bn)
TABLE 30 North America Breast Cancer Liquid Biopsy Market, by Country, 2023-2030 (US$ Bn)
TABLE 31 United States Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 32 United States Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 33 United States Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 34 United States Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 35 Canada Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 36 Canada Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 37 Canada Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 38 Canada Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 39 Mexico Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 40 Mexico Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 41 Mexico Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 42 Mexico Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 43 Europe Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 44 Europe Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 45 Europe Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 46 Europe Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 47 Europe Breast Cancer Liquid Biopsy Market, by Country, 2017-2022 (US$ Bn)
TABLE 48 Europe Breast Cancer Liquid Biopsy Market, by Country, 2023-2030 (US$ Bn)
TABLE 49 Germany Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 50 Germany Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 51 Germany Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 52 Germany Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 53 France Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 54 France Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 55 France Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 56 France Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 57 United Kingdom Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 58 United Kingdom Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 59 United Kingdom Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 60 United Kingdom Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 61 Italy Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 62 Italy Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 63 Italy Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 64 Italy Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 65 Spain Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 66 Spain Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 67 Spain Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 68 Spain Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 69 Rest of Europe Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 70 Rest of Europe Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 71 Rest of Europe Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 72 Rest of Europe Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 73 Asia Pacific Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 74 Asia Pacific Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 75 Asia Pacific Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 76 Asia Pacific Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 77 China Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 78 China Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 79 China Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 80 China Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 81 Japan Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 82 Japan Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 83 Japan Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 84 Japan Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 85 India Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 86 India Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 87 India Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 88 India Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 89 South Korea Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 90 South Korea Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 91 South Korea Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 92 South Korea Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 93 South-East Asia Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 94 South-East Asia Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 95 South-East Asia Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 96 South-East Asia Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 97 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 98 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 99 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 100 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 101 Latin America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 102 Latin America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 103 Latin America Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 104 Latin America Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 105 Brazil Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 106 Brazil Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 107 Brazil Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 108 Brazil Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 109 Argentina Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 110 Argentina Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 111 Argentina Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 112 Argentina Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 113 Rest of Latin America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 114 Rest of Latin America Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 115 Rest of Latin America Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 116 Rest of Latin America Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 117 Middle East and Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 118 Middle East and Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 119 Middle East and Africa Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 120 Middle East and Africa Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 121 GCC Countries Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 122 GCC Countries Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 123 GCC Countries Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 124 GCC Countries Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 125 South Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 126 South Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 127 South Africa Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 128 South Africa Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)
TABLE 129 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2017-2022 (US$ Bn)
TABLE 130 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market, by Circulating Biomarker, 2023-2030 (US$ Bn)
TABLE 131 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market, by End User, 2017-2022 (US$ Bn)
TABLE 132 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market, by End User, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global breast cancer liquid biopsy market?

The global breast cancer liquid biopsy market was valued at USD 0.3 Billion in 2022.

What is the expected growth rate of the breast cancer liquid biopsy market between 2023 and 2030?

The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% between 2023 and 2030, reaching USD 1.25 Billion in 2030.

Which segment is leading the market share in terms of circulating biomarkers?

Circulating tumor cells (CTCs) are the leading segment by circulating biomarkers, holding over 35% share in terms of value in 2022.

Which end-user segment governs the global demand for breast cancer liquid biopsy?

The hospitals & physician laboratories segment governs the global demand for breast cancer liquid biopsy, holding a massive share of over 35% in 2022.

Which circulating biomarkers segment will post the highest CAGR in the forecast period?

The cell-free DNA (cfDNA) segment will post the highest CAGR in the projected period.

Which region is fueling the growth of the breast cancer liquid biopsy industry?

Asia Pacific is fueling the rapid growth of the breast cancer liquid biopsy industry, with an over one-third share in 2022.

Who are the major global breast cancer liquid biopsy market players?

The top players include The Menarini Group, F. Hoffmann-La Roche Ltd, QIAGEN, and Thermo Fisher Scientific Inc. Other major players include NeoGenomics Laboratories, Myriad Genetics Inc, Biocept Inc, and Fluxion Biosciences Inc.

What are the major market drivers of the breast cancer liquid biopsy industry?

The rising prevalence of breast cancer, the increased need for non-invasive diagnostic procedures, and developments in liquid biopsy technology are the key market drivers.

What are the major market restraints of the breast cancer liquid biopsy industry?

The major market restraints are the high costs associated with liquid biopsy tests, regulatory challenges, and the need for skilled healthcare professionals trained in liquid biopsy techniques.

What are the major market opportunities of the breast cancer liquid biopsy industry?

The major market opportunities of the breast cancer liquid biopsy industry include the potential for early detection of tumor recurrence, the ability to monitor treatment response, and the development of innovative liquid biopsy technologies that enhance sensitivity and accuracy.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –